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SUMMARY - Insulin-like growth factor 1 (IGF-1) is a regulator of intrauterine growth, and 
circulating concentrations are reduced in intrauterine growth-restricted fetuses. The aim of our study 
was to investigate the relationship between IGF-1 levels in newborns and intrauterine growth,  
expressed as birth weight (BW). The research was designed as a cross-sectional study. The study  
included 71 premature newborns, gestational age (GA) ≤33 weeks. Quantitative determination of 
IGF-1 was performed in the 33rd post-menstrual week (pmw) to make the measurements more 
 comparable. We used an enzyme-bound immunosorbent test for quantitative determination of IGF-
1. Our results showed the mean IGF-1 level in premature newborns in 33rd pmw to be 23.1±4.56 
(range 15.44-39.75) μg/L. There was no difference in IGF-1 values between male (23.1±4.98 μg/L) 
and female (23.1±4.87 μg/L) newborns. There was no significant difference in the average IGF-1 
levels between male and female newborns with BW <50th and BW >50th percentile for GA either 
(p>0.50). Only BW <33rd percentile newborns had a statistically significantly lower IGF-1 level com-
pared to newborns with greater BW. Based on our results, it is concluded that serum IGF-1 level 
 reflects intrauterine growth only in BW <33rd percentile newborns. This fact could be used for further 
therapeutic purposes.
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Introduction
Intrauterine growth restriction (IUGR) is usually 
the end result of maternal, placental, fetal and genetic 
causes. Endocrine environment controls the growth of 
the fetus and endocrine causes are responsible for 
IUGR development1. Multiple hormonal interactions 
are able to produce a specific pattern of intrauterine 
development with potential lifelong consequences for 
health2. Fetal endocrine system also plays a significant 
role in helping the fetus adjust to extrauterine environ-
ment1,3.
Insulin-like growth factor 1 (IGF-1) is a polypep-
tide hormone produced mainly by the liver in response 
to the endocrine growth hormone stimulus, but it is 
also secreted by multiple tissues for autocrine/para-
crine purposes. During fetal life, IGF-1 is mostly se-
creted in the placenta4. IGF-1 possesses a wide num-
ber of own activities such as anabolic, antioxidant, an-
ti-inflammatory and cytoprotective actions5. Many 
authors have investigated the relationship between 
IGF-1 and diseases of prematurity6,7. IGF-1 is an 
 important regulator of fetal growth, and circulating 
concentrations are reduced in intrauterine growth-re-
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stricted fetuses8. The latest studies have shown positive 
correlation between birth weight (BW), gestational 
age (GA) and umbilical cord serum IGF-1 levels9,10. 
Also, these studies have shown that in humans, IUGR 
is correlated to high levels of serum IGF binding pro-
tein-1 (IGFBP-1)4. The IGF/IGFBP system is in-
volved in fetal growth, bone mineralization, and ener-
getic status in humans10,11. The IGFs are necessary for 
normal brain development and function, and may af-
fect brain growth and neurologic development12.
The list of roles of IGF-1 is increased, both in 
physiological and pathological conditions, underlying 
that its potential therapeutic options seem to be lim-
ited to those proven states of local or systemic IGF-1 
deficiency as a replacement treatment, rather than in-
creasing its upper normal range5.
The aim of the study was to investigate the rela-
tionship between IGF-1 levels in newborns and intra-
uterine growth expressed as BW, and secondly to de-
termine whether there was a difference in IGF-1 levels 
between male and female newborns.
Materials and Methods
This study was performed at Department of Neo-
natology, Clinical Center of Montenegro, Podgorica, 
after approval from the institutional Ethics Commit-
tee (consent number 03/01-3813/4). The mothers 
signed an informed consent to participate in the study. 
The study was designed as a cross-sectional study. The 
study included 71 premature newborns, GA ≤33 
weeks, hospitalized at Department of Neonatology, 
Clinical Center of Montenegro. Newborns with con-
spicuous congenital anomalies were not included in 
the study.
A database was formed including demographic 
data, data from pregnancy and delivery (GA) and an-
thropometric measures at birth (BW). In every new-
born included in the study, venous blood sample (0.5 
mL) was obtained in 33rd postmenstrual week (pmw) 
to make the measurements more reliable and com-
parable. The samples (serum) were frozen and stored 
in a freezer (-80 ºC) until completion of a series of 
samples. In all samples, quantitative determination 
of the requested biomarker (IGF-1) was performed 
 simultaneously, under the same conditions, using 
 immunochemical enzyme-linked immunosorbent as-
say (ELISA), a method widely used on this hormone 
measurement13.
For percentile average BW of male/female infants, 
we used the RCPCH UK-WHO Neonatal and Infant 
Close Monitoring Growth Chart 200914,15. Based on 
these growth charts, male and female newborns were 
divided into two subgroups of newborns with BW be-
low the 50th percentile (BW <50th) for GA and new-
borns with BW above the 50th percentile (BW >50th) 
for GA. We compared the mean levels of IGF-1 be-
tween the groups.
In the second step, we determined the 33rd percen-
tile (1481 g) of BW for the whole group of newborns 
and obtained two groups of BW below the 33rd per-
centile (BW <33rd) and BW above the 33rd percentile 
(BW >33rd). We compared the levels of IGF-1 be-
tween the groups.
Statistical data processing included calculation of 
descriptive measures, use of statistical tests and statis-
tical software programs (IBM, SPSS) for comparisons 
of parameters between the subgroups. Normality of 
data was tested by Kolmogorov-Smirnov test. The fol-
lowing statistical tests were used: Student’s t-test, 
ANOVA test, Kruskal-Wallis test with distinct post-
hoc tests (Tukey test for parametric ANOVA and 
Mann-Whitney U test for Kruskal-Wallis non-para-
metric test). Univariate associations were evaluated us-
ing Pearson’s correlation analysis. In all tests used, the 
level of statistical significance was set at p<0.05.
Results
There were 42 (59.15%) male and 29 (40.85%) fe-
male newborns. The mean BW of newborns in pri-
mary cohort was 1708.4±403.64 (range 990-2860) g, 
mean GA 31.2±1.87 (range 26-33) gestational weeks, 
and mean IGF-1 level 23.1±4.56 (range 15.44-39.75) 
mcg/L. Average BW (in grams) and percentiles of BW 
in groups with the same GA are shown in Tables 1 and 
2. Table 3 shows BW, GA and IGF-1 levels of male 
and female newborns. Student’s t-test revealed differ-
ence in BW, GA and IGF-1 level. Male newborns had 
a significantly higher BW, but there was no sex differ-
ence in GA. There was no difference in the levels of 
IGF-1 between male (23.2±4.98 mcg/L) and female 
(23.1±4.87 mcg/L) newborns (p>0.05; t=1.284).
To further explore the relationship of BW and 
IGF-1, we divided each group of participants (male and 
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female) into two subgroups of newborns with BW <50th 
percentile and newborns with BW >50th per centile.
There were 18 male newborns with BW <50th per-
centile and their mean BW was 1588.3±244.06 g. 
There were 24 male newborns with BW >50th percen-
tile and their mean BW was 1951.7±444.70 g.
There were 10 female newborns with BW <50th 
percentile and their mean BW was 1446±295.57 g. 
There were 19 female newborns with BW >50th per-
centile and their mean BW was 1653.2±382.33 g.
Gestational age and serum levels of IGF-1 are 
shown in Tables 4 and 5. The subgroups of male in-
fants did not differ according to GA (p>0.05; t=1.801) 
and there was no significant difference in the levels of 
IGF-1 (p>0.05; t=2.064) either. The subgroups of fe-
male newborns did not differ according to GA (p>0.05; 
t=1.745) and there was no significant difference in the 
levels of IGF-1 (p>0.05; t=2.758).
In the next step, the male and female groups were 
divided into two subgroups according to the cut-off 
Table 1. Average percentiles of birth weight (BW, grams) in male newborns (N=42) in groups of the same gestational 
age (GA)
GA (weeks) <10
th percentile <31st percentile  <50th percentile <66th percentile <90th percentile
BW (g) n BW (g) n BW (g) n BW (g) n BW (g) n
≤28 <890  <1080 1 <1150 1 <1200 1 <1400 1
29 <1000  <1150  <1290  <1350 1 <1590 1
30 <1110  <1350 1 <1425  <1500 1 <1800 3
31 <1210 <1500 2 <1600 <1700 2 <2000 1
32 <1370 <1700 2 <1800 3 <1900 2 <2200 6
33 <1570 <1880 5 <2000 3 <2120 2 <2500 2+1*
*one newborn with BW >90th percentile (BW=2860 g)  
Source: average BW of male infants (RCPCH UK-WHO Neonatal and Infant Close Monitoring Growth Chart 200914).
Table 2. Average percentiles of birth weight (BW, grams) in female newborns (N=29) in groups of the same gestational 
age (GA)
GA (weeks) <10
th percentile <31st percentile  <50th percentile <66th percentile <90th percentile
BW (g) n BW (g) n BW (g) n BW (g) n BW (g) n
≤28 <810  <1040  <1190 1 <1150 1 <1350 5
29 <900  <1120 1 <1200 1 <1300  <1500  
30 <1010  <1260  <1350  <1450 1 <1700 1
31 <1130 <1320 1 <1510 1 <1610 1 <1900 4
32 <1300 <1600 2 <1700 <1810 1 <2110
33 <1450 1 <1690 1 <1900 1 <1930 <2600 5
Source: average BW of female infants (RCPCH UK-WHO Neonatal and Infant Close Monitoring Growth Chart 200915).
Table 3. Birth weight (BW), gestational age (GA) and 
levels of insulin-like growth factor-1 (IGF-1) according 
to gender
Parameter Male, N=42 Female, N=29 p and t values**









*values expressed as mean ± SD; **Student’s t-test
33rd percentile (1481 g) of BW and compared accord-
ing to IGF-1 levels (Tables 6 and 7).
Tables 6 and 7 show the values of GA and IGF-1 
in male and female newborns below (BW <33rd) and 
above (BW >33rd) the 33rd percentile of BW. There 
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were 24 newborns with BW <33rd and 47 with BW 
>33rd percentile.
There were 11 male newborns with BW <33rd per-
centile (1301.8±157.09 g) and 31 male newborns with 
BW >33rd percentile (1971.3±317.98 g). There were 13 
female newborns with BW <33rd percentile (1253.1± 
127.63 g) and 16 female newborns with BW >33rd per-
centile (1848.8± 252.74 g).
Data analysis yielded a statistically significant dif-
ference in IGF-1 levels between the groups. The new-
borns (male and female) with BW <33rd percentile had 
a statistically significantly lower level of IGF-1 than 
the respective newborns with higher BW (male 
p<0.05, U=14 and female p<0.05, U=49).
Discussion and Conclusion
Intrauterine growth is a complex process involving 
maternal, placental and fetal factors of genetic, envi-
ronmental and nutritional nature. BW has served as a 
Table 7. Gestational age (GA) and levels of insulin-like 
growth factor-1 (IGF-1) in female newborns (N=29) 
according to birth weight (BW) cut-off value of 1481 g 






















Data expressed as mean ± SD; *IGF expressed as median (25th-75th 
percentile) because of data non-normality; BW 33rd percentile = 
1481 g; *Student’s t-test; **Mann-Whitney U test; b = female BW 
<33rd vs. female BW >33rd
Table 4. Gestational age (GA) and levels of insulin-like 
growth factor-1 (IGF-1) in male newborns (N=42)  



















*values expressed as mean ± SD; **Student’s t-test
Table 5. Gestational age (GA) and levels of insulin-like 
growth factor-1 (IGF-1) in female newborns (N=29) 



















*values expressed as mean ± SD; **Student’s t-test
Table 6. Gestational age (GA) and levels of insulin-like 
growth factor-1 (IGF-1) in male newborns according to 
birth weight (BW) cut-off value of 1481 g  






















Data expressed as mean ± SD; IGF expressed as median (25th-75th 
percentile) because of data non-normality; BW 33rd percentile = 
1481 g; *Student’s t-test; **Mann-Whitney U test; a = male BW 
<33rd vs. male BW >33rd
surrogate marker of fetal growth, nutrition and health. 
In this study, we used BW as a marker of fetal growth.
A growth-restricted fetus/newborn is character-
ized by an increased rate of fetal and neonatal mortal-
ity and morbidity and an increased risk of chronic 
adult diseases such as neurodevelopmental outcome, 
cardiovascular disease, diabetes and obesity16-18.
Many authors have clearly established that IGF-1 
is the main regulator of intrauterine growth, as con-
firmed by correlation between low BW and low cord 
serum IGF-111,19. However, some studies failed to 
show any association between intrauterine growth 
and IGF-17,20. Discrepancies in previous studies could 
partly be explained by difficulties in obtaining reliable 
measurements, common problems when studying 
newborns, especially preterms19.
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In our study, we obtained blood samples at 33rd 
pmw uniformly to reduce the possibility of error and 
to ensure better comparison of the results.
Our results showed that there was no significant 
difference in IGF-1 level between male and female 
newborns. Other authors report that female newborns 
have higher IGF-1 levels than males, explaining it by 
the size at birth being a composite of factors deter-
mined by gender21. Also, the IGF-1 levels in umbilical 
cord plasma were higher in female newborns, but con-
tributed positively to BW in both sexes22.
Our results showed that there was no statistically 
significant difference in IGF-1 levels between the 
newborns with BW <50th percentile and newborns 
with BW >50th percentile. The newborns (male and fe-
male) with BW <50th percentile had lower IGF-1 level 
than newborns with BW >50th percentile, but this dif-
ference was not statistically significant.
In the next step, the primary cohort was divided 
into two groups according to the cut-off 33rd percentile 
(BW 1481 g). We found a statistically significant be-
tween-group difference according to IGF-1 levels. 
Newborns with BW <33rd percentile had a significant-
ly lower IGF-1 level than newborns with higher BW. 
Other authors have reported similar results, indicating 
that IGF-1 reflects concurrent short-term growth ve-
locity in BW >33rd percentile newborns22.23.
Our results showed that there was no statistically 
significant difference in IGF-1 levels according to 
gender. IGF-1 levels of newborns below and above the 
50th percentile of BW according to GA showed no dif-
ference either. Only BW <33rd percentile newborns 
had a statistically significantly lower level of IGF-1. 
Based on our results, it is concluded that serum IGF-1 
levels reflect intrauterine growth only in BW <33rd 
percentile newborns.
According to our results, similar levels of IGF-1 in 
both male and female newborns facilitate interpreta-
tion of results and suggest uniform protocols (in both 
genders) for the use of IGF-1 in the treatment of 
IUGR.
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Sažetak
POVEZANOST INZULINU SLIČNOG FAKTORA RASTA TIP 1 I INTRAUTERINOG RASTA
L. Banjac, J. Kotur-Stevuljević, T. Gojković, V. Bokan-Mirković, G. Banjac i G. Banjac
Inzulinu sličan faktor rasta (IGF-1) je jedan od čimbenika koji utječu na intrauterini rast. Serumske razine IGF-1 su 
smanjene u fetusima s intrauterinim zastojem rasta. Cilj našega istraživanja bio je ispitati odnos između razine IGF-1 u 
nedonoščadi i intrauterinog rasta izraženog kao porođajna težina (PT). Istraživanje je provedeno kao presječna studija. U 
studiju je bilo uključeno 71 nedonošče gestacijske dobi (GD) ≤33 tjedna. Kvantitativno određivanje IGF-1 provedeno je u 
33. postmenstruacijskom tjednu (pmt) radi bolje usporedivosti rezultata. Za kvantitativno određivanje IGF-1 rabili smo 
enzimski imunosorbentni test. Naši rezultati pokazali su da je srednja razina IGF-1 u nedonoščadi u 33. pmt iznosila 
23,1±4,56 (raspon 15,44-39,75) μg/L. Nije bilo razlike u vrijednostima IGF-1 između muške (23,1±4,98 μg/L) i ženske 
(23,1±4,87 μg/L) nedonoščadi. Također nije bilo značajne razlike u srednjim razinama IGF-1 između nedonoščadi s PT <50. 
i PT >50. percentila za GD (p>0,50). Nedonoščad s niskom PT (<33. percentila) imala su statistički značajno nižu razinu 
IGF-1. Na temelju naših rezultata može se zaključiti da serumska razina IGF-1 odražava intrauterini rast samo u nedo-
noščadi male PT (<33. percentila), što bi mogao biti koristan podatak za buduću uporabu IGF-1 u terapijske svrhe.
Ključne riječi: Novorođenče; Inzulinu sličan faktor rasta I; Fetusni rast, retardacija; Presječna istraživanja
